Articles tagged with Drug Candidates
Researchers from Monash University and international partners have developed a potential new malaria drug candidate targeting dihydroorotate dehydrogenase enzyme. The team's work has been hailed as significant in combating malaria, which kills up to one million people annually worldwide.
Tiny LNA-based compounds developed by Santaris Pharma A/S successfully inhibit entire microRNA families, targeting cancer, viral infections, and cardiovascular diseases. The high affinity and target specificity of these compounds enable functional inhibition without off-target effects.
The company's lead drug candidate, omecamtiv mecarbil, directly activates cardiac myosin, increasing cardiac function without changing contraction rates. This novel mechanism may provide a new therapeutic strategy for improving cardiac performance in patients with systolic heart failure.
A tiny polypeptide has been developed that can bind to target-seeking molecules, enhancing their properties and improving the efficiency of drug development. The concept presents a new approach to drug development, potentially allowing for rapid development of new drugs with reduced costs and time.
Researchers have identified a preclinical candidate that may slow the natural decline in memory associated with ageing. The new synthetic compound selectively blocks an enzyme involved in high levels of 'stress' steroid hormones, which are linked to memory loss.
A research team led by Scripps Research Institute has discovered a promising new drug candidate to treat malaria, which shows an attractive safety profile and potential for treatment in a single oral dose. The study's findings provide hope for the development of new treatments against this deadly disease.
The TB Alliance has made significant progress in developing new TB drugs, with three co-developed by the organization and its partners, and two others currently being tested through the Critical Path to TB Regimens (CPTR) initiative.
Scientists have identified a new approach to tackling human African trypanosomiasis (HAT), also known as sleeping sickness. A valid drug target has been found and leads for orally administered drugs have been identified, showing promise for effective treatment of the disease.
A team of researchers from Pitt and Walter Reed Army Institute of Research have identified compounds that hold promise for treating leishmaniasis, a parasitic infection affecting millions worldwide. The newly developed strategy, called HILCES, uses high-throughput screening to identify effective drug candidates.
The development of siRNA drugs is hindered by a strong immune response that can cause toxic side effects. Researchers are exploring mechanisms for inducing this response and strategies for minimizing its effects.
Researchers at LSTM and UoL aim to develop a new antimalarial drug that targets a novel enzyme in Plasmodium falciparum, potentially eliminating malaria symptoms. The project will use computational techniques and molecular modeling to design effective inhibitors.
A study by Gerry Stefanatos and team found that dextroamphetamine improved speech processing in patients with Broca's aphasia and Anomic aphasia, suggesting the drug may enhance brain repair and therapy outcomes.
VIB researchers found a way cells can detect nutrients via transceptors, similar to hormone signaling. This discovery offers promising possibilities for treating metabolic diseases by targeting newly discovered receptor proteins.
Researchers have identified five compounds that block the activity of the trypanosomal REL1 enzyme, which is crucial for the parasite's survival. The approach uses computational tools to predict the dynamics of proteins and test hundreds of compounds for their ability to inhibit the enzyme.
Researchers have created a new therapy for preventing heart failure by developing a highly selective drug that blocks the production of aldosterone. The compounds were synthesized and tested in cell cultures and rat models, showing promising results.
A new Web-based resource is being developed to provide molecular data needed for computer-aided drug design. The resource aims to improve the prediction of potential drug candidates and advance biomedical research.
Regeneron's ARCALYST (rilonacept) has been shown to effectively manage symptoms of Cryopyrin-Associated Periodic Syndromes (CAPS), a rare inherited disease. The treatment demonstrated an 84% improvement in overall symptom scores and high patient response rates.
Researchers isolated over two dozen novel compounds that could serve as backup anti-viral drugs against avian flu. These compounds showed potentially stronger or equal inhibition than current remedies, including Tamiflu and Relenza.
Researchers at Saint Louis University have made a breakthrough finding that a smallpox drug, hexadecyloxypropyl-cidofovir (CMX001), successfully targets adenovirus in animal models. CMX001 provided protection from the virus when administered prophylactically or therapeutically and reduced viral load to undetectable levels.
Research at Harvard University found that drugs approved on tight FDA deadlines are more likely to face later regulatory action for safety concerns. The study suggests that a more flexible approval protocol could improve drug safety and reduce rushed approvals.
Scientists at Sirtris developed potent SIRT1 activators, 1000 times more effective than resveratrol, to treat Type 2 Diabetes and age-related diseases. These findings hold promise for a new approach to treating metabolic and other diseases of aging.
A study by Jason Dyck at the University of Alberta found that a protein responsible for transporting fat into heart cells may be a key to preventing age-related decline in heart function. Genetically modified mice with this protein deficiency showed no accumulated fat in their hearts and outperformed normal aged mice on a treadmill test.
Contrave significantly reduced food intake in both lean and obese mice by targeting the ventral tegmental area, a key region of the reward pathway. The combination of bupropion and naltrexone resulted in a 94% reduction of food intake in obese mice, demonstrating potential for effective weight loss treatment.
Researchers create an array of magnetic-field sensors to detect tiny magnetic spheres, which can bind with cell receptors. This technology enables rapid evaluation of potential antiviral drugs and high-precision detection of cancer biomarkers.
Diarrheal diseases kill over 2 million children annually, and the Institute for OneWorld Health aims to combat this with novel anti-secretory drugs. The $46 million grant will support the development of new treatments to complement traditional approaches.
The University of North Carolina has received a $21.3 million grant from the Bill & Melinda Gates Foundation to develop new treatments for late-stage African sleeping sickness and visceral leishmaniasis. The project aims to create affordable therapies for diseases affecting hundreds of thousands of people in developing nations.
A promising new TB drug candidate, SQ109, has been cleared for Phase I clinical trials following a successful public-private partnership between NIAID and Sequella. Developed with extensive support from NIAID, SQ109 holds potential for treating the virtually untreatable disease XDR-TB.
Research demonstrates zebrafish as an efficient and effective animal model for assessing human cancer cells at various stages of tumorigenesis, with significant findings including conserved cell signaling mechanisms and the ability to visualize cell migration and angiogenesis formation in vivo.
A newly isolated compound, nostocarboline, has been shown to be a potent inhibitor of cholinesterase, a brain chemical linked to Alzheimer's disease progression. Its potency is comparable to an existing cholinesterase inhibitor, and it holds promise as a potential treatment for mild to moderate forms of the disease.
A new biochip tool called MetaChip can analyze drug candidates for toxicity and eliminate harmful ones before they advance to pre-clinical stages. The technology mimics the effects of metabolism in the human liver, enabling early detection of toxic compounds that could be difficult to predict or find with current testing methods.
Scientists at the University of Arizona have created melanotropin-based drugs with improved properties that can selectively target specific receptors. These compounds show promise in treating various conditions, including cancer, sexual dysfunction, and eating disorders.
The Infectious Diseases Society of America states that endocarditis and meningitis are better treated with bactericidal drugs, while urinary tract infections can be effectively managed with bacteriostatic drugs. Corticosteroids are recommended for bacterial meningitis to prevent inflammation.
Ganguly's work involves designing drugs from natural molecules, targeting disease-causing compounds, and exploring new mechanisms of treatment. His notable achievements include developing Ziracin, a natural antibiotic, and Zetia, a cholesterol-lowering drug with a synergistic effect with statins.
Scientists at Max-Planck-Institute for Molecular Physiology develop a new concept for more efficient search of drug candidates. By employing biologically relevant natural products as starting point, the 'domain concept' aims to increase hit rate in compound libraries.
Researchers developed a superoxide dismutase (SOD) enzyme mimetic that significantly reduced inflammation and tissue damage in an animal model of colitis. The SOD mimetic M40403 also reduced elevated cytokine levels and diarrhea, marking promising results for potential clinical candidates.
Researchers found that DiaPep277 modulates the immune system to prevent autoimmune diabetes progression. The study showed significant increases in C-peptide levels and reductions in insulin requirements among patients receiving DiaPep277.
MetaPhore will develop and test a highly active SOD mimetic to protect heart tissues from damage. The research aims to provide additional mechanistic information on the role of superoxide in reperfusion injury, which may also apply to other ischemic events.
Researchers have found that an enzyme mimetic compound significantly improves the functioning of blood vessels and nerves in diabetic animal studies, reducing vascular abnormalities and nerve damage. The study suggests a potentially significant new approach for treating and preventing complications associated with diabetes.
A new bar coding system developed by Purdue University chemists can quickly identify the most biologically active compounds among thousands of candidates. The method uses standard spectrometers and reduces the laborious process to a few hours, cutting down time needed to identify active compounds to zero.
Purdue University researchers have developed a method to sort and isolate chemical compounds as they are made, identifying the most biologically active compounds among millions of candidates. The new method combines state-of-the-art imaging technology and combinatorial chemistry, reducing screening times by four to 12 times.